Graft-versus-host disease following marrow transplantation for aplastic anemia: Different impact of two GVHD prevention strategies

Bone Marrow Transplantation

Volumn 42, Issue 1, 2008, Pages 51-56

  Siegal, D ^a   Xu, W ^b   Sutherland, R ^c   Kamel Reid, S ^c   Kuruvilla, J ^a   Lipton, J H ^a   Minden, M ^a   Messner, H ^a   Gupta, V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; ITRACONAZOLE; MESNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; APLASTIC ANEMIA; ARTICLE; BLADDER DISEASE; BONE MARROW TRANSPLANTATION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; GASTROINTESTINAL DISEASE; GRAFT FAILURE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEART DISEASE; HUMAN; INCIDENCE; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MALE; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK REDUCTION; STOMATITIS; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BONE MARROW TRANSPLANTATION; CALCINEURIN; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 48949116752     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.88     Document Type: Article

References (26)

1. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P et al Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68 119-125.
2. Storb R, Leisenring W, Deeg HJ, Anasetti C, Appelbaum F, Bensinger W et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic, anemia. Blood 1994; 83: 2749-2750.
3. Locatelli F, Bruno B, Zecca M, Van-Lint MT, McCann S, Arcese W et al Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: Results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
4. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ et al Cyplophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39-44.
5. Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004; 103: 2490-2497.
6. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP et al. Long-term outcome after marrow transplantation for severe aplastic: Anemia. Blood 1998; 91: 3637-3645.
7. Syrjala KL, Langer SL, Abrams JR, Storer B, Sanders JE, Flowers ME et al. Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA 2004; 291: 2335-2343.
8. Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004; 10: 867-876.
9. Gupta V, Ball SE, Sage D, Ortin M, Freires M, Gordon-Smith EC et al Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005; 35: 467-471.
10. Avivi I, Chakrabarti S, Milligan DW, Waldmann H, Hale G, Osman H et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Morrow Transplant 2004; 10: 186-194.
11. Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis PD, Osman H et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: High incidence but low mortality. Br J Haematol 2002; 119: 1125-1132.
12. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
13. Rzepecki P, Sarosiek T, Szczylik C. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome-single center experience. Jpn J Clin Oncol 2006; 36: 46-49.
14. Juliusson G, Theorin N, Karlsson K, Frodin U, Malin C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: Influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006; 37: 503-510.
15. Incidence of aplastic anemia: The relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood 1987; 70: 1718-1721.
16. Gerrie A, Marsh J, Lipton JH, Messner H, Gupta V. Marrow transplantation for severe aplastic anemia with significant renal impairment. Bone Marrow Transplant 2007; 39: 311-313.
17. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
19. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
20. Flowers ME, Traina F, Storer B, Maris M, Bethge WA, Carpenter P et al Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant 2005; 35: 277-282.
21. Gupta V, Daly A, Lipton JH, Hasegawa W, Chun K, Kamel-Reid S et al Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 2005; 11: 764-772.
22. Nollet F, Billiet J, Selleslag D, Criel A. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant 2001; 28: 511-518.
23. Passweg JR, Socie G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM et al. Bone marrow transplantation for severe aplastic anemia: Has outcome improved? Blood 1997; 90: 858-864.
24. George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant 2007; 40: 13-18.
25. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stein cell transplantation: A cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383-388.
26. Chakrabarti S, Buyck H, Ball S, O'Regan L, Rice P, Marsh J. Epstein-Barr virus associated lymphoproliferative disorder following allogeneic transplantation for acquired aplastic anaemia: The role of prior immunosuppressive therapy and intensity of conditioning. Bone Marrow Transplant 2007; 39 (Suppl. 1): S165 (abstr. 709).